LBL-007 (Anti-Lag3 Monoclonal Antibody):
"Characterization of a Novel Anti-Human Lymphocyte Anti-Human Lymphocyte Activation Gene 3 (LAG-3) Antibody for Cancer Immunotherapy " published in MABS 2019 (thesis).
LBL-024: A Bispecific Antibody:
"An Anti-PD-L1 and 4-1BB Bispecific Antibody With Highly Differentiated Binding Affinity, Shows Anti-Tumor Efficacy In A Mouse Tumor Model " Accepted by 2021-AACR
LBL-015: a Bispecific Fusion Protein:
"A Novel Anti-PD-1 Fused with TGF-βR2, Shows A Great Anti-Tumor Activity In A Mouse MC38 Model " Accepted by 2021 AACR
LBL-007 (Anti-Lag3 Monoclonal Antibody):
"Phase I Study of LBL-007, A Novel Anti-Human Lymphocyte Activation Gene 3 (LAG-3) Antibody In Patients with Advanced Solid Tumors " Accepted by 2021-ASCO
Wechat QR code
Leads Biolabs © Nanjing Leads Biolabs Co.,Ltd. | 苏ICP备18069235号-1
